肾综合征出血热患者血凝抑制抗体的动态检测及其临床意义  

Dynamics and Clinical Significance of Hemagglutination- Inhibiting Antibody in Patients with Hemorrhagic Fever with Renal Syndrome

作　　者：樊万虎[1] 张成文[1] 田君喜 刘清珍[1] 

机构地区：[1]西安医科大学第一临床医学院,陕西省预防医学研究所

出　　处：《中华实验和临床病毒学杂志》1994年第4期368-370,共3页Chinese Journal of Experimental and Clinical Virology

摘　　要：以鼠脑血凝素作为抗原，用微量血凝抑制试验（ＨＩＴ）对确诊的１４例肾综合征出血热（ＨＦＲＳ）患者１０８价系列血清进行检测。血凝抑制抗体第３病日即可检出，第４～５病日阳性率为８８．９％，第６～７病日达９４．４％，提示检测此抗体可用于ＨＦＲＳ的早期诊断。抗体滴度第３～４病日始上升，第８～１３病日明显升高，第１７～１８病日达高峰；危重型随病日延长抗体水平下降，危重型与轻、中、重型有显著差异。因此，早期检测此抗体的水平及动态检测此抗体滴度的变化将直接反映患者的预后和转归。The dynamics of hemagglutination-inhibiting antibody (HIAb)in 14 patients with hemorrhagic fever HFRS were determined by micro-hemagglutinail on inhibition test(Micro-HI),using Hantaan viral hemagglutinin purified from brains of infected albino mics as the antigen. HIAb was detectable on day 3 after the onest of the disease.Its positive rates on day 4-5 and 6-7 were 88.9% and 94.5%,respectively.The HIAb titre began to rise on day 3-4 after the onset of the disease (febrile stage),rose to a high level during day 9-13(lateoligouria to early polyuria stage), and reached its peak on day 17-18 (recovery stage).In critically sicked patients, the HIAb titre was declining with the increase of days after the onset of HFRS.The HIAb titre in critically sicked patients was signuificantly different from that detected in the other three types of patients(P<0.d1).These results suggested that the HIAb dyanamics in HFRS patients might directly reflect the prognosis of the patients, and that the HI test could be used in early diagnosis and epidemiologic investigation of HFRS.

关 键 词：血凝抑制试验 血凝抑制抗体 肾病综合征 出血热 

分 类 号：R512.804[医药卫生—内科学]